– Live moderated video webcast with members of
management to discuss its ongoing Phase 1/2 study of core
technology in development, Annamycin for the treatment of Acute
Myeloid Leukemia, on Wednesday, September
28th at 11:00 AM
HOUSTON, Sept. 23,
2022 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) (Moleculin or the Company), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting highly resistant tumors and viruses, today announced that
Walter V. Kemp, Founder, President,
CEO and Chairman, and Wolfram C. M.
Dempke, MD, PhD, MBA, European Chief Medical Officer of
Moleculin will participate in the Virtual Investor Innovations in
Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.
As part of the virtual event, the Company will discuss it's
next-generation anthracycline, Annamycin, and its ongoing clinical
development for the treatment of AML for people who are refractory
to or relapsed after induction therapy. The ongoing Phase 1/2 trial
(MB-106) evaluating Annamycin in combination with Cytarabine (also
known as "Ara-C" and for which the combination of Annamycin and
Ara-C is referred to as AnnAraC) is an open label trial that builds
on the safety and dosage data from two successfully concluded
single agent Annamycin AML Phase 1 trials (MB-104 and MB-105) in
the U.S. and Europe, respectively,
and the preclinical data from the Company's sponsored research
In addition to the moderated portion of the event, investors and
interested parties will have the opportunity to submit questions.
The Company will answer as many questions as possible during the
A live video webcast of the Event will be available on the
Events page of the Investors section of the Company's
website (moleculin.com). A webcast replay will be available two
hours following the live presentation and will be accessible for
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of drug
candidates for the treatment of highly resistant tumors and
viruses. The Company's lead program, Annamycin, is a
next-generation anthracycline designed to avoid multidrug
resistance mechanisms with little to no cardiotoxicity. Annamycin
is currently in development for the treatment of relapsed or
refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator designed to be capable of inhibiting
p-STAT3 and other oncogenic transcription factors while also
stimulating a natural immune response, targeting brain tumors,
pancreatic and other cancers; and WP1220, an analog to WP1066, for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in the development of a portfolio of antimetabolites,
including WP1122, for the potential treatment of COVID-19 and other
viruses, as well as cancer indications including brain tumors,
pancreatic and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
JTC Team, LLC
View original content to download
SOURCE Moleculin Biotech, Inc.